BPC-157 From a Compounding Pharmacy Now: 2026 HHS Policy Guide

Can a compounding pharmacy make BPC-157 now for injury pain? Yes, in one narrow way. A federal HHS enforcement discretion policy, which Holland & Knight reports was published October 28, 2026, says HHS does not intend to take action against a state-licensed 503A compounding pharmacy that prepares BPC-157 for one specific patient with a prescription and meets a list of conditions. If an injury has kept you up at night, a headline like this can feel like a door opening, so here is the plain version: what the policy allows, how long it lasts, and the questions to take to your pain clinician and pharmacist.

Disclosure: Heads up, some links on this page are affiliate links. If you buy through one of them, this site may earn a commission. This costs you nothing extra.

Quick facts as of November 13, 2026

Can a compounding pharmacy make BPC-157 now?

Yes, under the policy’s conditions. Section 503A covers state-licensed pharmacies that compound for a specific patient with a prescription, and the HHS policy applies to those pharmacies. Holland & Knight’s policy summary lays out the scope.

Olympia Pharmaceuticals calls itself a “premier FDA-registered 503B outsourcing facility and 503A pharmacy.” In its Olympia Pharmaceuticals press release dated November 12, 2026, the company says its 503A pharmacy will begin compounding select peptides. It plans to launch BPC-157 first (“initially”) for patients with a valid prescription, and to make covered peptides available “by December.” Its president, Joshua Fritzler, says patients should get these peptides from a pharmacy with a prescription.

Restorative Compounding, a different pharmacy, says in an October 29 blog post that it can compound all six covered peptides today. That is the pharmacy’s own claim, and it shows how one pharmacy is describing the new policy to patients. Restorative Compounding blog post

What the HHS policy allows, in plain terms

Holland & Knight lists ten conditions, and all ten must be met:

1. The peptide is on the policy’s Appendix A list.
2. The product matches Appendix B for sequence, structure, molecular weight, formula and route limits.
3. The bulk substance comes from an FDA-registered facility with a valid certificate of analysis covering identity, purity, potency and harmful contaminants.
4. The original manufacturer is FDA-registered and CGMP-compliant, its location appears on the certificate of analysis, and any repacker or reseller has validated it.
5. Serious adverse events and quality issues are reported to MedWatch and the relevant state or states.
6. The label reads “This is a compounded drug product. Not for resale.”
7. The product contains only one active ingredient from Appendix A.
8. For oral forms, there is documentation of adequate oral bioavailability in humans.
9. The only co-packaged device is an FDA 510(k)-cleared syringe.
10. All other requirements of the federal Food, Drug, and Cosmetic Act are met, including a patient-specific prescription and state pharmacy rules.

Holland & Knight says state rules still apply and that states may restrict these peptides. The full policy text is in the HHS policy PDF, which is worth reading next to any summary.

Which peptides and forms does the policy cover?

The policy names six peptides and the forms allowed for each, as Holland & Knight describes Appendix B. Olympia’s release lists the order in which it plans to offer them.

What happened in 2026, and when?

• July 2026: According to Restorative’s blog, FDA’s Pharmacy Compounding Advisory Committee reviewed seven peptides and voted to recommend six for the 503A bulk substances list.
• October 28, 2026: Holland & Knight gives this as the Federal Register publication date for the policy.
• November 12, 2026: Olympia Pharmaceuticals issues its press release.
• November 13, 2026: Written comments are due, according to Holland & Knight.

Some summaries label the date and status differently, so confirm both in the Federal Register notice. Holland & Knight says the policy lasts until a final rule addresses each peptide, and that HHS may revisit it in whole or in part if a safety signal or product quality issue arises. Its own analysis, labeled separately from the policy text, calls the policy less durable than inclusion on the bulks list through rulemaking. Olympia says the policy aims to discourage use of research-use-only peptides from foreign manufacturers while FDA reviews the substances.

Is BPC-157 FDA-approved now?

The policy is enforcement discretion, not FDA approval, and it is not evidence that BPC-157 is safe or helps injury pain.

Enforcement discretion is the term to remember. Restorative’s blog describes it as the government stating that it intends to refrain from action against a state-licensed pharmacy or licensed physician who compounds these peptides for a specific patient. Holland & Knight’s summary adds that the policy creates no rights for anyone.

Restorative’s blog says BPC-157 is “studied for its potential role in tissue repair, gut health, and musculoskeletal recovery.” Those are the pharmacy’s words about the peptide. For a broader look at the research, see peptides safety evidence (our research library).

Why is BPC-157 on an FDA safety list?

FDA’s FDA category 2 list includes BPC-157. FDA describes that category as bulk drug substances that “may present significant safety risks.” The FDA entry for BPC-157 says compounded drugs containing it “may pose risk for immunogenicity” for certain routes of administration. Immunogenicity means the chance that the body’s immune system reacts to a substance. The entry also flags peptide-related impurities and the complexity of characterizing the ingredient.

The policy’s conditions focus on ingredient sourcing, certificates of analysis and labeling.

Is BPC-157 hard on the kidneys?

The FDA entry for BPC-157 describes immune reactions and impurities. For kidney questions, your prescriber or pharmacist is the right person to ask. Ask whether your kidney history or any medicine you already take changes the picture, and bring the full list described in your medication list for a pain-care visit.

Which seven peptides is FDA reviewing?

The HHS policy covers six: BPC-157, TB-500, KPV, MOTS-c, epitalon and semax. Restorative’s October 29 blog post says the July 2026 advisory committee reviewed seven peptides and recommended six. It adds: “A seventh peptide reviewed at the same time was not recommended.” To find the name of that seventh peptide, search FDA’s advisory committee pages for the July 2026 meeting, or ask your pharmacist.

Can you trust a compounding pharmacy?

A 2013 review in Drugs in R&D looked at the potential risks of pharmacy compounding. The 2013 review of pharmacy compounding risks says compounded drugs are exempt from good manufacturing practice (GMP) rules and that testing to assess product quality is inconsistent. It also cites published testing reports, including work by the FDA and state agencies, showing that compounded drugs “fail to meet specifications at a considerably higher rate than FDA-approved drugs.”

Restorative’s blog lists the checks it says it runs: potency and identity, sterility, endotoxin control, and documentation and traceability. Ask any pharmacy you consider for the same paperwork. Olympia says it holds active licenses in 49 states, and you can check any pharmacy’s state license with your state board of pharmacy.

For more on safety questions that apply to any new medicine, see medicine and procedure safety.

Who does this affect, and what are the common mix-ups?

Holland & Knight describes the policy as covering state-licensed pharmacies, federal facilities and licensed physicians compounding under section 503A. For you as a patient, the route is a prescription from a licensed prescriber, filled by a licensed pharmacy.

What should I ask my pain clinician and my pharmacist?

For your pain clinician or prescriber:

• Does BPC-157 fit my injury, and what other treatments have been tried so far?
• If it fits, which form would you prescribe: injection, oral or topical?
• Does my kidney history, or any medicine I already take, change the picture?
• What would tell us it is helping, and when should we check back?
• If numbness, weakness or a sudden change shows up, what is the plan?

For your pharmacist:

• Can you show the certificate of analysis for the bulk BPC-157, and which facility made it?
• Is the original manufacturer FDA-registered?
• Does the label read “This is a compounded drug product. Not for resale.”?
• Is the syringe FDA 510(k)-cleared?
• How do you report serious adverse events to MedWatch?
• What is today’s price, and what does it include? Ask for it in writing, since prices change.

What should I track, and what should I say at the visit?

Keep a simple log: the date the injury started, what you have tried, how the pain changes from week to week, and any new symptoms or side effects. If numbness, weakness or pain that changes suddenly shows up after an injury, read when pain changes suddenly before anything else.

At the visit, you could say: “I read that a compounding pharmacy can now make BPC-157 with a prescription under an HHS policy. Can we talk about whether it fits my injury, and what you would want me to track?”

By the Pain Care Questions Team

This article is for general information purposes only and does not constitute medical advice. Consult your doctor or qualified healthcare provider before making changes to your health routine.